MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1

Journal of Experimental Medicine

Volumn 208, Issue 3, 2011, Pages 439-454

  Ruprecht, Claudia R ^a   Krarup, Anders ^a   Reynell, Lucy ^a   Mann, Axel M ^a   Brandenberg, Oliver F ^a   Berlinger, Livia ^a   Abela, Irene A ^a   Regoes, Roland R ^b   Günthard, Huldrych F ^a   Rusert, Peter ^a   Trkola, Alexandra ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GLYCOPROTEIN GP 120; VIRUS ANTIBODY;

ANIMAL CELL; ARTICLE; BINDING SITE; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; THERMODYNAMICS; VIRION; VIRUS NEUTRALIZATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BLOTTING, WESTERN; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; KINETICS; NEUTRALIZATION TESTS; VIRION; VIRUS SHEDDING;

EID: 79952732800     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20101907     Document Type: Article

References (71)

1. Alam, S.M., M. Morelli, S.M. Dennison, H.X. Liao, R. Zhang, S.M. Xia, S. Rits-Volloch, L. Sun, S.C. Harrison, B.F. Haynes, and B. Chen. 2009. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc. Natl. Acad. Sci. USA. 106:20234-20239. doi:10.1073/pnas.0908713106
2. Allaway, G.P., K.L. Davis-Bruno, G.A. Beaudry, E.B. Garcia, E.L. Wong, A.M. Ryder, K.W. Hasel, M.C. Gauduin, R.A. Koup, J.S. McDougal, et al. 1995. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses. 11:533-539. doi:10.1089/aid.1995.11.533
3. Bánki, Z., L. Kacani, P. Rusert, M. Pruenster, D. Wilflingseder, B. Falkensammer, H.J. Stellbrink, J. van Lunzen, A. Trkola, M.P. Dierich, and H. Stoiber. 2005. Complement dependent trapping of infectious HIV in human lymphoid tissues. AIDS. 19:481-486. doi:10.1097/01.aids.0000162336.20439.8d (Pubitemid 40515851)
4. Barbas, C.F. III, E. Björling, F. Chiodi, N. Dunlop, D. Cababa, T.M. Jones, S.L. Zebedee, M.A. Persson, P.L. Nara, E. Norrby, et al. 1992. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc. Natl. Acad. Sci. USA. 89:9339-9343. doi:10.1073/pnas.89.19.9339
5. Binley, J.M., C.S. Cayanan, C. Wiley, N. Schülke, W.C. Olson, and D.R. Burton. 2003. Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions. J. Virol. 77:5678-5684. doi:10.1128/JVI.77.10.5678-5684.2003
6. Binley, J.M., T. Wrin, B. Korber, M.B. Zwick, M. Wang, C. Chappey, G. Stiegler, R. Kunert, S. Zolla-Pazner, H. Katinger, et al. 2004. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78: 13232-13252. doi:10.1128/JVI.78.23.13232-13252.2004 (Pubitemid 39507829)
7. Buchacher, A., R. Predl, K. Strutzenberger, W. Steinfellner, A. Trkola, M. Purtscher, G. Gruber, C. Tauer, F. Steindl, A. Jungbauer, et al. 1994. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res. Hum. Retroviruses. 10:359-369. doi:10.1089/aid.1994. 10.359 (Pubitemid 24141210)
8. Buzon, V., G. Natrajan, D. Schibli, F. Campelo, M.M. Kozlov, and W. Weissenhorn. 2010. Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions. PLoS Pathog. 6:e1000880. doi:10.1371/journal.ppat.1000880
9. Cardoso, R.M., F.M. Brunel, S. Ferguson, M. Zwick, D.R. Burton, P.E. Dawson, and I.A. Wilson. 2007. Structural basis of enhanced binding of extended and helically constrained peptide epitopes of the broadly neutralizing HIV-1 antibody 4E10. J. Mol. Biol. 365:1533-1544. doi:10.1016/j.jmb.2006.10.088 (Pubitemid 46048836)
10. Chen, L., Y.D. Kwon, T. Zhou, X. Wu, S. O'Dell, L. Cavacini, A.J. Hessell, M. Pancera, M. Tang, L. Xu, et al. 2009. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science. 326:1123-1127. doi:10.1126/science.1175868
11. Chertova, E., J.W. Bess Jr., B.J. Crise, R.C. Sowder II, T.M. Schaden, J.M. Hilburn, J.A. Hoxie, R.E. Benveniste, J.D. Lifson, L.E. Henderson, and L.O. Arthur. 2002. Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus. J. Virol. 76:5315-5325. doi:10.1128/JVI.76.11.5315-5325.2002 (Pubitemid 34517882)
12. Corti, D., J.P. Langedijk, A. Hinz, M.S. Seaman, F. Vanzetta, B.M. Fernandez-Rodriguez, C. Silacci, D. Pinna, D. Jarrossay, S. Balla- Jhagjhoorsingh, et al. 2010. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS ONE. 5:e8805. doi:10.1371/journal.pone.0008805
13. Daar, E.S., X.L. Li, T. Moudgil, and D.D.C. Ho. 1990. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc. Natl. Acad. Sci. USA. 87:6574-6578. doi:10.1073/pnas.87.17.6574
14. Deen, K.C., J.S. McDougal, R. Inacker, G. Folena-Wasserman, J. Arthos, J. Rosenberg, P.J. Maddon, R. Axel, and R.W. Sweet. 1988. A soluble form of CD4 (T4) protein inhibits AIDS virus infection. Nature. 331:82-84. doi:10.1038/331082a0 (Pubitemid 18053422)
15. Finnegan, C.M., W. Berg, G.K. Lewis, and A.L. DeVico. 2002. Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion. J. Virol. 76:12123-12134. doi:10.1128/JVI.76.23.12123-12134. 2002
16. Finzi, A., S.H. Xiang, B. Pacheco, L. Wang, J. Haight, A. Kassa, B. Danek, M. Pancera, P.D. Kwong, and J.C. Sodroski. 2010. Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-triggered conformational transitions. Mol. Cell. 37:656-667. doi:10.1016/j.molcel.2010.02. 012
17. Frey, G., H. Peng, S. Rits-Volloch, M. Morelli, Y. Cheng, and B.C. Chen. 2008. A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proc. Natl. Acad. Sci. USA. 105:3739-3744. doi:10.1073/pnas. 0800255105 (Pubitemid 351723468)
18. Frey, G., J. Chen, S. Rits-Volloch, M.M. Freeman, S. Zolla-Pazner, and B. Chen. 2010. Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies. Nat. Struct. Mol. Biol. 17: 1486-1491. doi:10.1038/nsmb.1950
19. Gorny, M.K., A.J. Conley, S. Karwowska, A. Buchbinder, J.Y. Xu, E.A. Emini, S. Koenig, and S. Zolla-Pazner. 1992. Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J. Virol. 66:7538-7542.
20. Haase, A.T. 2010. Targeting early infection to prevent HIV-1 mucosal transmission. Nature. 464:217-223. doi:10.1038/nature08757
21. Haim, H., Z. Si, N. Madani, L. Wang, J.R. Courter, A. Princiotto, A. Kassa, M. DeGrace, K. McGee-Estrada, M. Mefford, et al. 2009. Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state. PLoS Pathog. 5:e1000360. doi:10.1371/journal.ppat.1000360
22. Hessell, A.J., L. Hangartner, M. Hunter, C.E. Havenith, F.J. Beurskens, J.M. Bakker, C.M. Lanigan, G. Landucci, D.N. Forthal, P.W. Parren, et al. 2007. Fc receptor but not complement binding is important in antibody protection against HIV. Nature. 449:101-104. doi:10.1038/nature06106 (Pubitemid 47373775)
23. Hessell, A.J., P. Poignard, M. Hunter, L. Hangartner, D.M. Tehrani, W.K. Bleeker, P.W. Parren, P.A. Marx, and D.R. Burton. 2009a. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 15:951-954. doi:10.1038/nm.1974
24. Hessell, A.J., E.G. Rakasz, P. Poignard, L. Hangartner, G. Landucci, D.N. Forthal, W.C. Koff, D.I. Watkins, and D.R.C. Burton. 2009b. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 5:e1000433. doi:10.1371/journal.ppat.1000433
25. Hessell, A.J., E.G. Rakasz, D.M. Tehrani, M. Huber, K.L. Weisgrau, G. Landucci, D.N. Forthal, W.C. Koff, P. Poignard, D.I. Watkins, and D.R.C. Burton. 2010. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J. Virol. 84:1302-1313. doi:10.1128/JVI.01272-09
26. Ho, J., S. Moir, L. Kulik, A. Malaspina, E.T. Donoghue, N.J. Miller, W. Wang, T.W. Chun, A.S. Fauci, and V.M. Holers. 2007. Role for CD21 in the establishment of an extracellular HIV reservoir in lymphoid tissues. J. Immunol. 178:6968-6974. (Pubitemid 46847423)
27. Huber, M., and A. Trkola. 2007. Humoral immunity to HIV-1: neutralization and beyond. J. Intern. Med. 262:5-25. doi:10.1111/j.1365-2796.2007.01819.x (Pubitemid 47000630)
28. Huber, M., M. Fischer, B. Misselwitz, A. Manrique, H. Kuster, B. Niederöst, R. Weber, V. von Wyl, H.F. Günthard, and A.C. Trkola. 2006. Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection. PLoS Med. 3:e441. doi:10.1371/journal.pmed.0030441
29. Kilby, J.M., S. Hopkins, T.M. Venetta, B. DiMassimo, G.A. Cloud, J.Y. Lee, L. Alldredge, E. Hunter, D. Lambert, D. Bolognesi, et al. 1998. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4:1302-1307. doi:10.1038/3293 (Pubitemid 28512112)
30. Kunert, R., F. Rüker, and H. Katinger. 1998. Molecular characterization of five neutralizing anti-HIV type 1 antibodies: identification of nonconventional D segments in the human monoclonal antibodies 2G12 and 2F5. AIDS Res. Hum. Retroviruses. 14:1115-1128. doi:10.1089/aid.1998.14.1115 (Pubitemid 28409164)
31. Kwong, P.D., R. Wyatt, J. Robinson, R.W. Sweet, J. Sodroski, and W.A. Hendrickson. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 393:648-659. doi:10.1038/31405 (Pubitemid 28289647)
32. Kwong, P.D., M.L. Doyle, D.J. Casper, C. Cicala, S.A. Leavitt, S. Majeed, T.D. Steenbeke, M. Venturi, I. Chaiken, M. Fung, et al. 2002. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature. 420:678-682. doi:10.1038/nature01188 (Pubitemid 36764500)
33. Lewis, N., J. Williams, D. Rekosh, and M.L.C. Hammarskjöld. 1990. Identification of a cis-acting element in human immunodeficiency virus type 2 (HIV-2) that is responsive to the HIV-1 rev and human T-cell leukemia virus types I and II rex proteins. J. Virol. 64:1690-1697. (Pubitemid 20104907)
34. Lok, S.M., V. Kostyuchenko, G.E. Nybakken, H.A. Holdaway, A.J. Battisti, S. Sukupolvi-Petty, D. Sedlak, D.H. Fremont, P.R. Chipman, J.T. Roehrig, et al. 2008. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat. Struct. Mol. Biol. 15:312-317. doi:10.1038/nsmb.1382 (Pubitemid 351654038)
35. Mascola, J.R., G. Stiegler, T.C. VanCott, H. Katinger, C.B. Carpenter, C.E. Hanson, H. Beary, D. Hayes, S.S. Frankel, D.L. Birx, and M.G. Lewis. 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6:207-210. doi:10.1038/72318 (Pubitemid 30082367)
36. McDougal, J.S., M.S. Kennedy, S.L. Orloff, J.K. Nicholson, and T.J. Spira. 1996. Mechanisms of human immunodeficiency virus Type 1 (HIV-1) neutralization: irreversible inactivation of infectivity by anti-HIV-1 antibody. J. Virol. 70:5236-5245. (Pubitemid 26240696)
37. McKeating, J.A., A. McKnight, and J.P. Moore. 1991. Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization. J. Virol. 65:852-860.
38. Mehandru, S., B. Vcelar, T. Wrin, G. Stiegler, B. Joos, H. Mohri, D. Boden, J. Galovich, K. Tenner-Racz, P. Racz, et al. 2007. Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. J. Virol. 81:11016-11031. doi:10.1128/JVI.01340-07 (Pubitemid 47536075)
39. Moir, S., A. Malaspina, Y. Li, T.W. Chun, T. Lowe, J. Adelsberger, M. Baseler, L.A. Ehler, S. Liu, R.T. Davey Jr., et al. 2000. B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells. J. Exp. Med. 192:637-646. doi:10.1084/jem.192.5.637
40. Montero, M., N.E. van Houten, X. Wang, and J.K.C. Scott. 2008. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol. Mol. Biol. Rev. 72:54-84. doi:10.1128/MMBR.00020-07 (Pubitemid 351398055)
41. Moore, J.P., J.A. McKeating, R.A. Weiss, and Q.J. Sattentau. 1990. Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science. 250:1139-1142. doi:10.1126/science.2251501 (Pubitemid 120031823)
42. Moore, J.P., J.A. McKeating, Y.X. Huang, A. Ashkenazi, and D.D. Ho. 1992. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates. J. Virol. 66:235-243.
43. Moore, P.L., E.T. Crooks, L. Porter, P. Zhu, C.S. Cayanan, H. Grise, P. Corcoran, M.B. Zwick, M. Franti, L. Morris, et al. 2006. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J. Virol. 80:2515-2528. doi:10.1128/JVI.80.5.2515-2528.2006 (Pubitemid 43271557)
44. Muster, T., F. Steindl, M. Purtscher, A. Trkola, A. Klima, G. Himmler, F. Rüker, and H. Katinger. 1993. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67:6642-6647. (Pubitemid 23309131)
45. Orloff, S.L., M.S. Kennedy, A.A. Belperron, P.J. Maddon, and J.S. McDougal. 1993. Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4. J. Virol. 67:1461-1471. (Pubitemid 23067653)
46. Pancera, M., S. Majeed, Y.E. Ban, L. Chen, C.C. Huang, L. Kong, Y.D. Kwon, J. Stuckey, T. Zhou, J.E. Robinson, et al. 2010. Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc. Natl. Acad. Sci. USA. 107:1166-1171. doi:10.1073/pnas.0911004107
47. Park, E.J., M.K. Gorny, S. Zolla-Pazner, and G.V.J.C. Quinnan Jr. 2000. A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex. J. Virol. 74:4183-4191. doi:10.1128/JVI.74.9.4183-4191.2000 (Pubitemid 30214424)
48. Pietzsch, J., J.F. Scheid, H. Mouquet, F. Klein, M.S. Seaman, M. Jankovic, D. Corti, A. Lanzavecchia, and M.C.C. Nussenzweig. 2010. Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness. J. Exp. Med. 207:1995-2002. doi:10.1084/jem.20101176
49. Poignard, P., T. Fouts, D. Naniche, J.P. Moore, and Q.J.C. Sattentau. 1996. Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation. J. Exp. Med. 183:473-484. doi:10.1084/jem.183.2.473 (Pubitemid 26059512)
50. Poignard, P., M. Moulard, E. Golez, V. Vivona, M. Franti, S. Venturini, M. Wang, P.W. Parren, and D.R.C. Burton. 2003. Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J. Virol. 77:353-365. doi:10.1128/JVI.77.1.353-365.2003 (Pubitemid 36004975)
51. Pugach, P., S.E. Kuhmann, J. Taylor, A.J. Marozsan, A. Snyder, T. Ketas, S.M. Wolinsky, B.T. Korber, and J.P. Moore. 2004. The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4. Virology. 321:8-22. doi:10.1016/j.virol.2003. 12.012 (Pubitemid 38368098)
52. R Development Core Team. 2008. R: A language and environment for statistical computing. Vienna Austria R Foundation for Statistical Computing. Vol. 1 (09/18/2009). Available at http://www.r-project.org.
53. Ramratnam, B., S. Bonhoeffer, J. Binley, A. Hurley, L. Zhang, J.E. Mittler, M. Markowitz, J.P. Moore, A.S. Perelson, and D.D. Ho. 1999. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet. 354:1782-1785. doi:10.1016/S0140-6736(99)02035-8
54. Rusert, P., H. Kuster, B. Joos, B. Misselwitz, C. Gujer, C. Leemann, M. Fischer, G. Stiegler, H. Katinger, W.C. Olson, et al. 2005. Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors. J. Virol. 79:8454-8469. doi:10.1128/JVI.79.13.8454-8469.2005 (Pubitemid 40853547)
55. Rusert, P., A. Mann, M. Huber, V. von Wyl, H.F. Gunthard, and A. Trkola. 2009. Divergent effects of cell environment on HIV entry inhibitor activity. AIDS. 23:1319-1327. doi:10.1097/QAD.0b013e32832d92c2
56. Salazar-Gonzalez, J.F., M.G. Salazar, B.F. Keele, G.H. Learn, E.E. Giorgi, H. Li, J.M. Decker, S. Wang, J. Baalwa, M.H. Kraus, et al. 2009. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J. Exp. Med. 206:1273-1289. doi:10.1084/jem.20090378
57. Sattentau, Q.J., S. Zolla-Pazner, and P. Poignard. 1995. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology. 206:713-717. doi:10.1016/S0042-6822(95)80094-8
58. Schoeni-Affolter, F., B. Ledergerber, M. Rickenbach, C. Rudin, H.F. Günthard, A. Telenti, H. Furrer, S. Yerly, and P. Francioli; Swiss HIV Cohort Study. 2010. Cohort profile: the Swiss HIV Cohort study. Int. J. Epidemiol. 39:1179-1189. doi:10.1093/ije/dyp321
59. Selinka, H.C., T. Giroglou, T. Nowak, N.D. Christensen, and M. Sapp. 2003. Further evidence that papillomavirus capsids exist in two distinct conformations. J. Virol. 77:12961-12967. doi:10.1128/JVI.77.24.12961-12967.2003 (Pubitemid 37494291)
60. Stiegler, G., R. Kunert, M. Purtscher, S. Wolbank, R. Voglauer, F. Steindl, and H. Katinger. 2001. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses. 17:1757-1765. doi:10.1089/ 08892220152741450 (Pubitemid 34114213)
61. Trkola, A., M. Purtscher, T. Muster, C. Ballaun, A. Buchacher, N. Sullivan, K. Srinivasan, J. Sodroski, J.P. Moore, and H. Katinger. 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70:1100-1108. (Pubitemid 26029030)
62. Trkola, A., H. Kuster, C. Leemann, A. Oxenius, C. Fagard, H. Furrer, M. Battegay, P. Vernazza, E. Bernasconi, R. Weber, et al; Swiss HIV Cohort Study. 2004. Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point. Blood. 104:1784-1792. doi:10.1182/blood-2004-01-0251
63. Trkola, A., H. Kuster, P. Rusert, B. Joos, M. Fischer, C. Leemann, A. Manrique, M. Huber, M. Rehr, A. Oxenius, et al. 2005. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. 11:615-622. doi:10.1038/nm1244
64. Turville, S.G., J.J. Santos, I. Frank, P.U. Cameron, J. Wilkinson, M. Miranda-Saksena, J. Dable, H. Stössel, N. Romani, M. Piatak Jr., et al. 2004. Immunodeficiency virus uptake, turnover, and 2-phase transfer in human dendritic cells. Blood. 103:2170-2179. doi:10.1182/blood-2003-09-3129 (Pubitemid 38326235)
65. Walker, L.M., S.K. Phogat, P.Y. Chan-Hui, D. Wagner, P. Phung, J.L. Goss, T. Wrin, M.D. Simek, S. Fling, J.L. Mitcham, et al; Protocol G Principal Investigators. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 326:285-289. doi:10.1126/science.1178746
66. Witz, J., and F. Brown. 2001. Structural dynamics, an intrinsic property of viral capsids. Arch. Virol. 146:2263-2274. doi:10.1007/s007050170001 (Pubitemid 34682390)
67. Wu, X., Z.Y. Yang, Y. Li, C.M. Hogerkorp, W.R. Schief, M.S. Seaman, T. Zhou, S.D. Schmidt, L. Wu, L. Xu, et al. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 329:856-861. doi:10.1126/science.1187659
68. Yu, H.J., M.A. Reuter, and D.C. McDonald. 2008. HIV traffics through a specialized, surface-accessible intracellular compartment during transinfection of T cells by mature dendritic cells. PLoS Pathog. 4:e1000134. doi:10.1371/journal.ppat.1000134
69. Zhou, T., L. Xu, B. Dey, A.J. Hessell, D. Van Ryk, S.H. Xiang, X. Yang, M.Y. Zhang, M.B. Zwick, J. Arthos, et al. 2007. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature. 445:732-737. doi:10.1038/nature05580 (Pubitemid 46279718)
70. Zwick, M.B., and D.R. Burton. 2007. HIV-1 neutralization: mechanisms and relevance to vaccine design. Curr. HIV Res. 5:608-624. doi:10.2174/ 157016207782418443 (Pubitemid 351210995)
71. Zwick, M.B., A.F. Labrijn, M. Wang, C. Spenlehauer, E.O. Saphire, J.M. Binley, J.P. Moore, G. Stiegler, H. Katinger, D.R. Burton, and P.W. Parren. 2001. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75:10892-10905. doi:10.1128/JVI.75.22.10892-10905.2001 (Pubitemid 33034579)